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Fibrinolysis activation occurs almost universally after severe trauma. Systemic 
hyperfibrinolysis is a key component of Acute Traumatic Coagulopathy and associated with 
poor clinical outcomes, although controversy exists over optimal treatment strategies. The 
mechanistic drivers and dynamics of fibrinolytic activation in response to injury and trauma 
resuscitation are currently unclear. Furthermore, therapeutic triggers are compounded by 
the lack of a sensitive and rapid diagnostic tool, with discrepancy between hyperfibrinolysis 
diagnosed by viscoelastic hemostatic assays versus biomarkers for fibrinolysis. . ROTEM and 
TEG appear capable of detecting the severest forms of hyperfibrinolysis but are relatively 
insensitive to moderate, yet clinically significant fibrinolytic activation. Rapid evaluation of 
the current status of the fibrinolytic system remains a challenge and therefore the decision 
whether to administer an antifibrinolytic agent should be based upon available evidence 
from clinical trials. In line with current European guidelines, we recommend that all bleeding 
trauma patients, and in particular severely injured patients with evidence of hemorrhagic 
shock, should receive early empiric tranexamic acid. This review explains our current 
knowledge of the pathophysiological pathways which induce hyperfibrinolysis in trauma 
hemorrhage, evaluates the available diagnostic modalities and describes current treatment 
strategies.   
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Fibrinolysis activation occurs almost universally following severe injury.1 Physiological 
fibrinolysis is a proportionate response to increased fibrin generation following tissue 
trauma2, whereas excessive or systemic fibrinolytic activation is inappropriate and 
potentially lethal. Acute Traumatic Coagulopathy (ATC) is an early and endogenous 
hemostatic abnormality of which global hypocoagulation, systemic hyperfibrinolysis3 , early 
fibrinogen depletion and platelet dysfunction4 are key components. ATC is triggered by 
massive tissue injury in conjunction with hypoperfusion (shock) in the early phase after 
major trauma.3 Hyperfibrinolysis, is defined by disproportionately increased fibrinolytic 
activity with respect to fibrin formation5, and is associated with poor clot integrity, excessive 
bleeding and worse coagulopathy, in addition to increased morbidity and mortality.6   
 
Controversy currently exists over patient selection for antifibrinolytic therapy7 and is a 
reflection of our limited understanding of both the mechanism and dynamics of fibrinolytic 
activation after traumatic injury. Hyperfibrinolysis in trauma has yet to be properly defined 
with many different arbitrary definitions used in the literature (Table 1). Sensitive 
diagnostics for a rapid and current assessment of the fibrinolytic system are lacking2 despite 
the increasing use of viscoelastic hemostatic assays (VHA) (e.g. rotational 
thromboelastometry (ROTEM; Tem International GmbH, Munich, Germany) and 
thromboelastography (TEG; Haemonetics, Braintree, USA)) to define fibrinolytic activation 
states. Correlation of lysis parameters with laboratory gold standards of fibrinolysis e.g. 
plasmin-α2-antiplasmin complex (PAP) levels has proven difficult to interpret, and therefore 
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the clinical sequela of acute hyperfibrinolysis and/or early hypofibrinolysis has yet to be 
accurately described. In particular, the impact of a highly activated (or inhibited) fibrinolytic 
system on bleeding risk, organ failure and thrombotic complications is unclear. 
Understanding the drivers of trauma-induced fibrinolysis, the temporal relationship to injury 
and resuscitation, as well as optimal treatment strategies are priorities for the trauma 
research community. The purpose of this review is to explain our current knowledge of the 
pathophysiological pathways which induce hyperfibrinolysis in trauma hemorrhage, 
evaluate the available diagnostic modalities and describe current treatment strategies.   
 
Regulation of fibrinolysis 
The coagulation and fibrinolytic systems are both activated following trauma and exist in a 
dynamic equilibrium.1,8 Plasmin both degrades fibrin and prevents propagation of the clot 
distant to the site of injury. Plasminogen may be activated either by tissue-type or urinary-
type plasminogen activators (tPA and uPA respectively) or by the contact pathway. tPA is a 
serine protease produced and secreted primarily by pre-capillary arteriole and post-capillary 
venule endothelial cells9–11  and is the primary plasminogen activator in the vasculature. In 
response to vascular injury or the presence of thrombin, additional stores of tPA from 
endothelial Weibel-Palade bodies12 and possibly by poorly characterized other small storage 
granules13 are released.14   
 
Fibrinolytic activation is tightly controlled by plasminogen activator inhibitor 1 (PAI-1) which 
principally inhibits tPA and α-2 antiplasmin (α2AP) which inhibits plasmin. PAI-1 is found 
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within two distinct pools within the blood - plasma and platelets.15 Circulating levels of PAI-1 
are relatively low in comparison to the rich source within platelet α-granules.15 Platelet-rich 
thrombi are resistant to tPA-mediated fibrinolysis16, however, platelet contribution to 
plasma levels of PAI-1 and the degree to which platelets modulate trauma-induced 
hyperfibrinolysis is uncertain. Whilst initial studies suggested that only 10% of platelet PAI-1 
was in an active configuration17–19, subsequent research has discovered that platelets 
actually retain high levels of active PAI-120,21, capable of complexing and inactivating the 
plasminogen activators. Moore et al.22 demonstrated that platelet lysate mixed with whole 
blood ex vivo, resulted in a faster clotting time and reduced tPA-mediated fibrinolysis 
measured by TEG, in accordance with earlier studies describing the anti-fibrinolytic function 
of platelet PAI-1.16,23 Platelets are additionally a source of α2AP16, thrombin activatable 
fibrinolysis inhibitor (TAFI)24 and factor XIII25, all of which promote clot stabilization. 
Platelet-mediated fibrinolytic inhibition could in theory explain the improved outcomes 
associated with early transfusion of high ratios of platelets to red blood cells in patients with 
traumatic hemorrhage.26–28 Characterization of the antifibrinolytic capacity of platelets, and 
the efficacy of platelet transfusions on clot stability following trauma is therefore a research 
priority.  Importantly, recent studies have indicated platelets also contain profibrinolytic 
properties (outlined in the paper by White in this issue of Seminars in Thrombosis and 
Hemostasis), which should be considered in such studies.29 
 
The fibrinolytic system in traumatic coagulopathy   
ATC is an endogenous process, driven by the combination of endothelial hypoperfusion and 
tissue injury,  with hyperfibrinolysis, hypocoagulation, increased thrombin generation and 
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early fibrinogen depletion identified as key components.3,30 Present in up to 25% of trauma 
patients, ATC occurs in the first hour after injury, before significant fluid resuscitation or 
hemodilution has occurred.31,32 During resuscitation of the bleeding trauma patient, ATC is 
compounded by ongoing blood loss and treatment strategies which utilize hypocoagulable 
fluids e.g. crystalloids, with ensuing hemodilution, hypothermia and acidemia development 
contributing to a global failure of the coagulation system. Trauma Induced Coagulopathy 
(TIC)33 describes collectively the innate component of ATC and all subsequent 
coagulopathies which develop, typically  iatrogenic and related to suboptimal fluid 
resuscitation or delayed hemorrhage control.34 A temporal switch in coagulation status from 
the initial hypocoagulability of TIC to a hypercoagulable response occurs over hours to days 
after major trauma.35,36 A biphasic response has similarly been described in the fibrinolytic 
system37,38 with an initial acceleration of clot lysis lasting for several hours after injury, 
followed by inhibition of fibrinolytic capacity lasting between four to eleven days.39   
 
Activation of the Protein C (PC) pathway has been identified in both clinical human studies 
and experimental animal models as a potential mediator of hyperfibrinolysis in ATC.40–43 In 
addition to its inhibitory effect on thrombin generation, activated protein C in excess binds 
to and neutralizes PAI-1, resulting in de-repression of shock-mediated tPA release from the 
endothelium leading to uninhibited activation of fibrinolysis.40,44,45 PAI-1 rather than TAFI 
appears to exert greater control over the fibrinolytic state after trauma.1,3 Gando and 
colleagues alternatively consider traumatic coagulopathy to reflect disseminated 
intravascular coagulation (DIC) with a fibrinolytic phenotype, characterized by activation of 
the tissue-factor dependent coagulation pathway, insufficient anticoagulant mechanisms 
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and increased fibrinolysis.46,47 Primary and secondary fibrin(ogen)olysis are considered to be 
pathologically activated following trauma in response to shock-induced endothelial tPA 
release46,48,49 and DIC respectively.47 Activation of neutrophil elastase-mediated fibrinolytic 
pathways is additionally believed to contribute to the hyperfibrinolytic state.50 Subsequently 
it is proposed that insufficient anticoagulant mechanisms (e.g. low protein C and 
antithrombin levels) combined with PAI-1-mediated inhibition of fibrinolysis shifts the 
patient into DIC with a thrombotic phenotype.46,47,51   
 
Central to both hypotheses is the mechanism of shock-induced hyperfibrinolysis. Tissue 
hypoperfusion in isolation e.g. cardiac arrest, is capable of initiating hyperfibrinolysis52,53 
and similarly increasing levels of tissue injury will initiate fibrinolysis3, evidenced on ROTEM 
by shortened lysis onset time (20% lysis of maximum clot firmness).52 Sympathoadrenal 
activation following severe trauma leads to a surge in circulating catecholamines which are 
hypothesized to contribute to coagulopathy and hyperfibrinolysis by means of endothelial 
activation and glycocalyx degradation.54,55 The combination of both tissue injury and 
hemorrhagic shock in patients suffering major trauma causes a surge in tPA release from the 
endothelium driving a massive fibrinolytic response.3,51 Almost 90% of severely injured 
patients defined as Injury Severity Score (ISS) > 15 have PAP levels on admission of at least 
twice the upper limit of normal.1 The fibrinolytic response to trauma and shock is a dynamic 
process which evolves over time and may be exacerbated further by clinical interventions 
e.g. surgery, resuscitation. When these changes occur, and the specific drivers for any up or 
down-regulation in the fibrinolytic pathways are not known, in part due to limitations in our 




Diagnosis of hyperfibrinolysis in trauma 
Detection of post-injury changes in the fibrinolytic system in a clinically meaningful 
timeframe (i.e. to guide therapy) is challenging. Diagnostics currently available to quantify 
fibrinolysis are laboratory measures of fibrin degradation, measurement of individual 
proteins of the fibrinolytic system and VHA. The Euglobulin Clot Lysis Time (ECLT)56,57 is a 
validated assessment of overall fibrinolysis in vivo, however has little clinical utility in 
trauma due to the prolonged assay time and loss of plasma inhibitors (i.e. antiplasmin) in 
the acidification process. A further limitation is that ECLT is performed on diluted platelet 
poor plasma rather than whole blood and it is not capable of assessing the response to 
antifibrinolytic therapy since these agents are normally discarded within the supernatant 
during processing.58 Excessive fibrin degradation may be indicated by raised D-dimer levels; 
however, elevated levels are encountered in most patients following injury1 and are strongly 
correlated to injury severity3. Kutcher et al.59 found that patients with VHA-detectable 
hyperfibrinolysis have significantly higher D-dimer levels but that as a clinical marker on its 
own, D-dimer was not predictive of hyperfibrinolysis after adjusting for injury severity and 
shock.    
 
The fibrinolytic response to trauma is characterized by quantification of specific fibrinolytic 
proteins and complexes which are primarily measured by ELISA.1,3,39,54,60–62 Measurement of 
tPA and PAP complex levels in combination with fibrinolytic inhibitor levels (PAI-1, α2AP, 
TAFI) enables a comprehensive albeit static assessment of the fibrinolytic system, but is 
confined to the research setting due to the time it takes to process each assay. A functional, 
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global assay (such as a viscoelastic test or a plasma-based clot lysis assay) may provide 
better overall evaluation of the status of the fibrinolytic system.63 Any increase in fibrinolytic 
activation (PAP>1500 µg/L, twice the upper limit of normal) has been shown to be 
associated with a 12-fold increase in 28-day mortality and greater transfusion requirements 
compared to those with ‘normal’ levels of fibrinolytic activity (PAP < 1500 µg/L).1 However, 
measurement of circulating levels of PAP or the downstream D-dimer fragment represents 
recent plasmin generation (and fibrinolysis) but not necessarily the extent of ongoing 
fibrinolysis. Development of a point-of-care test capable of rapidly quantifying the extent of 
fibrinolytic activation e.g. PAP or α2AP may assist in guiding therapy although in isolation 
would still only represent an assessment of prior fibrinolytic activity. However, in 
combination with a dynamic assay such as a VHA, both rapid and serial read-outs of 
fibrinolytic biomarker levels have the potential to better determine the degree of ongoing 
fibrinolysis.   
 
Role of VHA in trauma hemorrhage & diagnosis of hyperfibrinolysis 
The major advantage of VHAs over other diagnostics is near patient testing and speed, with 
provision of a comprehensive assessment of clot formation dynamics including fibrinolysis in 
whole blood. ROTEM and TEG are capable of rapidly diagnosing ATC64–66 and are superior to 
conventional clotting tests (e.g. Prothrombin Time) in predicting the need for massive 
transfusion in trauma.67 An international panel of trauma researchers has recommended 
that VHA use should be considered during the early phases of trauma resuscitation and 
remains the only test capable of diagnosing hyperfibrinolysis in a clinically relevant 
timeframe.68 However, the latest National Institute for Health and Care Excellence (NICE) 
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guideline on the management of major trauma69 concludes that there is currently 
insufficient evidence to support the superiority of VHA over standard laboratory coagulation 
tests to target treatment. A recent Cochrane systematic review has suggested that at 
present in the setting of trauma, VHA should only be used for research purposes.70 Whilst 
VHA can provide results rapidly, there is a need for randomized clinical trial data to 
ascertain any superiority over standard laboratory tests as a tool to guide trauma 
resuscitation.71,72 For these reasons European and UK guidelines69,73 currently recommend 
early empiric treatment of hyperfibrinolysis in the bleeding trauma patient rather than 
waiting for VHA-confirmation of increased fibrinolysis.     
 
Extrapolation of the incidence and outcomes associated with hyperfibrinolysis in trauma 
from the literature is confounded by a number of methodological issues: (1) inconsistency in 
threshold definitions for VHA detected hyperfibrinolysis; (2) lack of standardization of VHAs 
with consequent lab-to-lab variation; (3) wide variation in patient populations; (4) 
discrepancies in sampling protocols that vary between minutes of injury to 12 hours; and (5) 
a lack of clarity between VHA versus biomarker diagnosed hyperfibrinolysis. 
 
VHA detected hyperfibrinolysis is reported in 2 – 20% of trauma patients presenting to the 
Emergency Department (ED) and is associated with mortality rates up to 100% (Table 
1).59,64,74–80 Hyperfibrinolysis is currently defined by ROTEM as a reduction in maximum clot 
firmness (MCF) of greater than 15% (ML > 15%), 60 minutes after the onset of clot 
formation. The continuous ROTEM variable of lysis onset time (LOT) may detect severe 
hyperfibrinolysis faster53,81, although this has not been validated in trauma patients. Three 
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distinct temporal patterns of ROTEM-detected hyperfibrinolysis have been described: (1) 
fulminant lysis described as complete clot lysis (EXTEM ML of 100%) within 30 minutes and 
associated with the highest mortality; (2) intermediate lysis as that occurring between 30 
and 60 minutes; and (3) late lysis occurring beyond 60 minutes.75 Defining TEG 
hyperfibrinolysis according to the manufacturer’s recommendation of clot lysis exceeding 
7.5%, 30 minutes after maximum clot amplitude (LY30 > 7.5%), Cotton et al.78 reported 
hyperfibrinolysis to be uncommon but highly lethal.  Chapman et al.82 subsequently found 
the lower threshold of 3% to be superior at diagnosing clinically relevant hyperfibrinolysis 
and predicting both massive transfusion and mortality. Consequently, TEG hyperfibrinolysis 
is now widely defined as LY30 ≥ 3%.83–85  
 
Is VHA diagnosed fibrinolysis an accurate reflection of the status of the fibrinolytic system? 
VHAs accurately identify patients with the highest degree of fibrinolysis, but appears 
relatively insensitive at detecting lower levels of fibrinolytic activation1, through rapid 
inhibition of free tPA by PAI-1 following blood draw.86 Using a composite measure of PAP 
and VHA on admission to ED we have shown fibrinolytic activation following severe trauma 
to be extremely common.1 Patients without VHA hyperfibrinolysis (ML < 15%) were 
categorized as ‘normal’ fibrinolytic activity if PAP < 1500 µg/L and ‘moderate’ fibrinolytic 
activity if PAP >1500 µg/L. Patients with PAP > 1500 µg/L combined with VHA 
hyperfibrinolysis (ML > 15%) were classified as ‘severe’. Whilst only 5% of patients were 
classified as ‘severe’, the largest proportion of patients (57%) had ‘moderate’ fibrinolytic 
activation which was not detected by ROTEM. PAP levels were closely related to injury 
severity, with approximately 90% of patients with ISS>15 demonstrating biomarker 
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confirmed hyperfibrinolysis. In a similar study utilizing PAP and TEG, Cardenas et al.87 found 
that 45% of patients had PAP>1500 µg/L with an associated 6-fold increase in overall 
mortality despite there being no evidence of hyperfibrinolysis on TEG (median LY30 1.1 % 
(0.2 – 2.4) (Table 1).     
 
Differences in ROTEM and TEG methodology and the reagents used (Table 2) alters the 
sensitivity to fibrinolysis across platforms and individual assays. Harr et al.88 reported that 
functional fibrinogen TEG (FFTEG) and FIBTEM were comparable in their ability to detect 
fibrinolysis faster than the other VHA assays. KaolinTEG appears superior in its ability to 
detect fibrinolysis in a dose-dependent manner across various tPA concentrations whereas 
RapidTEG detects lysis at high concentrations of tPA only. The more powerful clot activation 
required to generate faster results by RapidTEG, results in a clot more resistant to tPA-
induced fibrinolysis which may result in under-diagnosis of hyperfibrinolysis. VHA and 
biomarkers of fibrinolysis by definition do not measure the same thing, PAP reflects prior 
activation of fibrinolysis in vivo whereas VHAs quantify coagulation and to some extent 
fibrinolytic potential Clarification of the status of the fibrinolytic system and  therapeutic 
requirements of a bleeding trauma patient with grossly elevated PAP or D-dimer levels, but 
does not  meet the diagnostic threshold for VHA hyperfibrinolysis is clearly a research 
imperative. 
 
The circumstances required for VHA to detect ‘severe’ hyperfibrinolysis have yet to be 
confirmed. In one study tPA levels of nearly five times normal and α2AP levels below 75% of 
normal were shown to be required before ROTEM hyperfibrinolysis was visualised.1 We 
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hypothesize that free tPA within the ROTEM cup is required to generate plasmin and that 
only in the presence of low antiplasmin levels is there reduced inhibition of newly formed 
plasmin, resulting in ROTEM-detectable hyperfibrinolysis. Platelet dysfunction may 
additionally influence the ability of VHA to detect hyperfibrinolysis since impairment of ADP-
induced platelet activation following trauma is associated with increased sensitivity to tPA-
mediated fibrinolysis.89 Alternatively the pattern of biomarker positive fibrinolysis with 
negative VHA lysis may represent prior excessive lytic activity which has rapidly reverted to 
normal or hypofibrinolysis during the early phase response to trauma. A further explanation 
may lie in the relative availability of promoters or inhibitors of fibrinolysis within the VHA 
with respect to thrombin generation potential since both clot strength and lysis are 
products of one another.   
 
At the opposite end of the spectrum, it is similarly unclear what the implications of low VHA 
fibrinolysis are for the trauma patient. Whilst the upper boundary for ‘normal’ VHA 
fibrinolysis (ML ≤ 15%90 or LY30 < 3%82) is commonly quoted, no lower boundary has been 
reported and it has recently been suggested that patients with VHA hypofibrinolysis have 
worse clinical outcomes.83,91 Further investigation is required to phenotype VHA 
hypofibrinolysis to understand whether all patients with this entity are the same. In 
particular what biomarker patterns are associated with VHA hypofibrinolysis, the 
mechanisms that drive low fibrinolytic activity, the temporal relationship with injury, shock 
and resuscitation as well as clinical sequela e.g. mortality, VTE, organ failure. Improvements 
in the sensitivity of existing VHAs or development of diagnostic tools with greater definition 
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to identify and characterize trauma patients with hyper or hypofibrinolysis are urgently 
required. 
 
Who should receive antifibrinolytic treatment? 
Patients with TIC are eight times more likely to die within the first 24 hours92 and more likely 
to require a massive transfusion44, with increased risk of multi-organ failure (MOF) and 
longer critical care and hospital stay.92 Correct patient selection for treatment of 
hyperfibrinolysis provides an opportunity to improve upon these poor outcomes but given 
the lack of a validated diagnostic tool in trauma hemorrhage, the decision of who to treat 
requires an evidence-based clinical decision. The CRASH-2 trial randomized 20,211 injured 
patients to receive an antifibrinolytic or placebo based on pragmatic inclusion of all adult 
trauma patients who were bleeding or were suspected to be bleeding.93 Patients who 
received empiric dosing of tranexamic acid (TXA) had a lower overall mortality (14.5% vs 
16%) and a lower risk of death due to bleeding (4.9% vs 5.7%). Subgroup analysis from 
CRASH-2 found the greatest survival benefit to be in those patients with a systolic blood 
pressure less than 75 mmHg93, and was confirmed in a single center retrospective UK 
study94 which additionally reported reduced MOF in shocked patients who received TXA. 
Similarly antifibrinolytic therapy administered empirically to military casualties with combat 
associated traumatic hemorrhage was associated with lower in-hospital mortality.95 Once 
again the greatest benefit was observed in patients requiring a massive transfusion with TXA 
independently associated with survival. Given the current lack of evidence regarding the 
diagnostic accuracy of VHA70 and in the context of clinical trial data to support empiric 
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antifibrinolytic therapy in suspected trauma hemorrhage93, withholding treatment for VHA 
confirmed hyperfibrinolysis cannot be recommended.  
 
How should hyperfibrinolysis be treated? 
The primary method of targeted reversal of hyperfibrinolysis in trauma is currently with the 
antifibrinolytic TXA. Important questions remain however over the optimal dosing regime, 
timing, which patient subgroup derives most benefit and later thrombotic events. Early 
hemorrhage control and reversal of shock may in theory attenuate fibrinolytic activation 
through improved endothelial oxygenation and reduced tPA generation. Damage control 
resuscitation with a balanced transfusion strategy including early fresh frozen plasma96 (a 
source of α2AP) and platelets may further dampen fibrinolytic activation97 through 
increased PAI-1 delivery.   
 
Evidence for the use of Tranexamic Acid in trauma 
TXA (trans-4-aminomethylcyclohexane-1-carboxylic acid) is a synthetic analogue of the 
amino acid lysine. It exerts an antifibrinolytic effect by competitively blocking the lysine 
binding sites on plasminogen, thereby preventing the interaction of plasmin(ogen) with 
fibrin98 and at higher concentrations is a non-competitive inhibitor of plasmin.99,100 First 
described over five decades ago100,101 TXA has found widespread global clinical application 
in part due to it being readily available, cheap and having a proven safety profile. It is used 
routinely in the elective surgical setting, including gynecological, orthopedic, cardiac and 
liver transplant surgery where it has been shown to reduce blood loss and the need for 
17 
 
blood transfusion without increased thromboembolic events.102,103 TXA is considered a 
relatively old pharmacological agent although is currently being evaluated in international 
clinical trials of traumatic intracranial bleeding (Clinical Randomization of an Antifibrinolytic 
in Significant Head Injury; CRASH-3)104, non-traumatic gastrointestinal (Hemorrhage 
Alleviation with Tranexamic acid – Intestinal system; HALT-IT)105 and postpartum 
hemorrhage (World Maternal Antifibrinolytic Trial; WOMAN)106.     
 
The seminal study of TXA use in trauma hemorrhage (CRASH-2) was the first trial to 
demonstrate improved survival from bleeding with an antifibrinolytic. TXA was administered 
as a 1g bolus over 10 minutes followed by a second 1g infusion over eight hours. The 
beneficial effects of early TXA therapy (bolus dose within 3 hours) in reducing all-cause 
mortality and death due to bleeding did not vary significantly by baseline risk of death.107 
TXA can therefore be administered safely to all patients with traumatic bleeding with no 
evidence to suggest it should be reserved only for high risk patients with the most severe 
hemorrhage.108 Performed in 40 countries, the CRASH-2 results did not identify any effect of 
geographical location on the efficacy of TXA on reducing death from bleeding.109 In fact, 
countries with the most advanced healthcare systems appeared to derive the greatest 
relative risk reduction. Hemorrhage is the leading cause of preventable death globally from 
trauma and empiric use of TXA within three hours of injury, is likely to save many lives109 
and be highly cost-effective.110,111     
 
TXA for the management of combat injury and hemorrhage was evaluated in the 
retrospective MATTERs95 and MATTERs II studies.112 In study of 896 combat casualties, the 
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MATTERs study concluded that patients receiving TXA (n=293) had a significantly lower 
overall in-hospital mortality (17.4% vs 23.9%). However, a potential confounding factor is 
that the TXA cohort received a greater volume of cryoprecipitate. In order to specifically 
address this, the MATTERs II study examined 1332 patients to investigate the effect of TXA 
and cryoprecipitate on survival. In-hospital mortality was highest in patients who received 
neither TXA nor cryoprecipitate (23.6%) and was lowest in patients who received both TXA 
and cryoprecipitate (11.6%). The individual benefit of TXA and cryoprecipitate therapy was 
similar; both associated with an odds ratio (OR) of 0.61 and 95% CIs of 0.42 to 0.89 and 0.40 
to 0.94 respectively. Combined TXA and cryoprecipitate therapy had an additive rather than 
a synergistic effect with an OR of 0.34 (95% CI, 0.20 – 0.58). Based upon this body of 
evidence, NICE69, the Cochrane Collaboration113, the Association of Anesthetists of Great 
Britain and Ireland (AAGBI)114 and the European “STOP the Bleeding Campaign”73,115 
recommend that empiric intravenous TXA be given to all trauma patients with active or 
suspected active hemorrhage as soon as possible and within three hours of injury. In order 
to achieve early administration, ideally within the first hour, it is recommended that 
procedures be in place for delivery of the first dose of TXA pre-hospital at the scene of 
injury.73 
 
The survival benefit from antifibrinolytic therapy is greatest when it is administered early, 
within the first hour following trauma.116 Whether patients with confirmed (biomarker or 
VHA diagnosed) hyperfibrinolysis derive additional benefit is not known. Furthermore the 
precise mechanism by which TXA confers survival benefit is unknown with some evidence to 
suggest it has anti-inflammatory action94,117,118 in addition to its primary anti-fibrinolytic 
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effects. As a result the relative efficacy of TXA on early bleeding vs late deaths from MOF 
and sepsis is unclear. Paradoxically, late administration beyond three hours in the CRASH-2 
trial was associated with increased risk of death due to bleeding. Possible explanations are 
that late delivery reflects poorer outcomes associated with delayed trauma care or is 
secondary to PAI-1-mediated suppression of fibrinolysis with resultant microvascular 
thromboses.46 If hyperfibrinolysis transitions rapidly into a hypofibrinolytic state then 
further blockade of fibrinolysis with delayed antifibrinolytic therapy has the potential to be 
harmful although the effects of TXA, or other agents on hypofibrinolysis have yet to be 
characterized. Recently, a novel hypothesis based on data from a murine model of severe 
Traumatic Brain Injury (TBI) has been proposed.119 Whilst both tPA and uPA levels in the 
brain increased following injury, they did so at different rates, with tPA peaking soon after 
TBI (within three hours) and uPA demonstrating a delayed peak after approximately eight 
hours. TXA blocks tPA-mediated fibrinolysis, however it actually enhances uPA-mediated 
fibrinolysis.120 The delayed and protracted rise in uPA following injury combined with the 
ability of TXA to enhance uPA-mediated fibrinolysis provides a potential mechanism for the 
paradox of increased hemorrhage-related mortality with delayed therapy. Further research 
to evaluate the importance of uPA-mediated fibrinolysis in non-TBI related trauma is 
required along with the potential role of therapeutics capable of attenuating both tPA and 
uPA in bleeding after major injury. 
 
Alternative antifibrinolytic therapy in trauma 
The alternate antifibrinolytic agents aprotinin and epsilon aminocaproic acid (EACA) have 
some unfavorable properties compared to TXA, hence were not selected for clinical trial 
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evaluation in trauma hemorrhage. Compared with TXA, the synthetic lysine analogue EACA 
is ten times less potent121 and has not been shown to be associated with reduced 
transfusion requirements in elective surgery.122 Aprotinin was withdrawn from the market 
after it was found to be associated with increased mortality in a randomized trial of patients 
undergoing cardiac surgery.123 However, due to methodological deficiencies with this study 
the conclusions were called into question and the European Medicines Agency have since 
lifted the suspension.124 Aprotinin is a potent, long acting antifibrinolytic and future clinical 
trials should be considered to determine the efficacy in trauma hemorrhage as well as any 
additional benefits over TXA. In the search for an ideal antifibrinolytic to treat 
hyperfibrinolysis, a greater understanding of the pathophysiology of fibrinolytic pathways in 
trauma is required to determine optimal pharmacodynamics and how best to monitor the 
effect of any drug on fibrinolytic activity. 
 
 
Thrombotic risk of antifibrinolytic therapy in trauma 
A principal concern with the use of antifibrinolytics is potentiation of a prothrombotic state, 
either immediately after trauma during increased thrombin generation, or during the acute 
phase of recovery from major injury. Without thromboprophylaxis, multi-trauma patients 
have a baseline risk of hospital-acquired venous thromboembolism (VTE) exceeding 50%125, 
with increasing age an important clinical predictor.126 As trauma care advances, more 
patients survive beyond the initial 24-hours from injury and consequently more patients will 
be at risk of VTE. Some authors are concerned VTE rates are influenced directly by 
antifibrinolytic therapy;7 however, TXA has been shown to improve survival and is often 
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administered to those at greatest risk of VTE (e.g. major trauma, shock, critical care 
utilization and invasive procedures). In the surgical setting, a recent meta-analysis 
concluded that the risk of thromboembolic events with antifibrinolytic use was uncertain.102 
In a retrospective cohort study of 872,416 patients undergoing total hip or knee 
arthroplasty in the United States, antifibrinolytic therapy was associated with lower rates of 
blood transfusion without any increase in VTE.127 CRASH-2 represents the largest 
randomized trial to evaluate antifibrinolytic use in trauma patients and found no increase in 
clinically significant vascular occlusive events with TXA compared to placebo (1.7% vs. 2.0%). 
In fact patients who received TXA had a lower incidence of myocardial infarction post-
injury.93 Whilst the MATTERs study reported higher unadjusted rates of VTE in patients 
receiving an antifibrinolytic (TXA vs. No TXA: PE, 2.7% vs. 0.3% and DVT, 2.4% vs. 0.2%), the 
difference was nonsignificant on multivariate analysis and the investigators attributed the 
difference to the higher injury burden and degree of shock in the TXA group.95   
 
In order to reduce the incidence of VTE in this inherently high-risk group of patients, rather 
than avoiding early antifibrinolytic therapy, future research should focus on the role of 
proactive targeted thromboprophylaxis. Development of new methods to monitor 
fibrinolytic status as the trauma patient transitions from hyperfibrinolysis to a 
hypofibrinolytic state would permit earlier insertion of retrievable vena cava filters, or use 
of higher prophylactic doses of anticoagulants. Additionally the role of antiplatelet therapy 





Fibrinolytic activation within the limitations of current assays, is presumed almost universal 
following trauma. Assessing hyperfibrinolysis through biomarker assays (e.g. PAP) remains 
the gold standard, and in comparison with VHA demonstrates the insensitivity of ROTEM 
and TEG for accurate diagnosis of increased fibrinolytic activation. Rapid evaluation of 
current or active fibrinolysis remains a challenge but whilst our understanding of available 
diagnostics improves, the decision whether to administer an antifibrinolytic agent should be 
based upon available evidence from clinical trials. In line with current European guidelines, 
we recommend that all bleeding trauma patients (both suspected and confirmed), those 
that require immediate blood transfusion and all severely injured patients with evidence of 
hemorrhagic shock receive early empiric antifibrinolytic therapy. 
 
Early empiric TXA is associated with a mortality benefit and is the current mainstay of 
treatment for hyperfibrinolysis in trauma. Which patient subgroups derive greatest benefit 
from reversal of hyperfibrinolysis, optimal timing, choice of drug and potential for increased 
thrombotic events with antifibrinolytics should be the focus for future research. Given the 
advances in pharma engineering since TXA was first described over 50 years ago, it seems 
unlikely that such an old drug whose mechanism of action in traumatic hemorrhage is 
unclear will remain the optimal agent to treat trauma patients. Improved understanding of 
the pathways that drive excessive fibrinolytic activation, including the role of uPA, may lead 
to the development of novel and more efficacious therapeutics. The fibrinolytic system is 
highly dynamic, evolving over time following injury and yet studies have on the whole been 
limited to measurement of fibrinolysis at the point of ED arrival. Future studies should focus 
on serial sampling to fully characterize the temporal changes that occur in the coagulation 
23 
 
and fibrinolytic systems in response not just to the initial trauma, but over subsequent 
hours and days following resuscitation, surgery and antifibrinolytic therapy. At present TXA 
remains the most studied drug in traumatic hemorrhage, with sufficient evidence of efficacy 
and safety to recommend early empiric administration for the treatment of 
hyperfibrinolysis. 
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 Table 1 - Summary of studies of hyperfibrinolysis in trauma 




% patients with 
hyperfibrinolysis 
Mortality - with 
hyperfibrinolysis (%) 




Levrat74 2008 ECLT < 90 minutes (and MCF ≤ 18 mm) 87 6% 100% 11% 
Schochl75 2009 EXTEM ML = 100% 33 100% 88% n/a 
Theusinger76 2011 EXTEM ML > 15% (552) a 13 patients b  77% 33% 
Tauber77 2011 EXTEM ML > 15% 334 7% 57% 11% 
Kutcher59 2012 EFI > 10% 115 20% 52% 13% 
 
TEG studies 
Carroll65 2009 LY60 > 15% 161 2% 67% 8% 
Kashuk80 2010 EPL > 15% 61 18% 64% 24% 
Cotton78 2012 LY30 > 7.5% 1996 2% 76% 10% 
Ives79 2012 EPL > 15% 118 11% 92% 10% 
Chapman82 2013 LY30 ≥ 3% 73 15% 64% 18% 
Pommerening85 2014 LY30 > 3% 1625 11% 18% 10% 
Moore91 2014 LY30 ≥ 3% 180 18% 44% n/a 
Moore83 2016 LY30 ≥ 3% 2540 18% 34% n/a 
 
Biomarker studies 
Raza1 2013 PAP >1500 µg/L AND EXTEM ML < 15% (moderate) 
PAP >1500 µg/L AND EXTEM ML > 15% (severe) 





Cardenas62 2014 PAP 1500 – 20000 µg/L (moderate) 
PAP >20000 µg/L (severe) 






a Includes trauma and non-trauma patients presenting to the ED 
b Denominator for trauma patients not available   
c No fibrinolysis defined as PAP < 1500 µg/L 
ECLT, euglobulin clot lysis time; EPL, estimated percent lysis; EFI, enzymatic fibrinolysis index (EXTEM ML – APTEM ML); LY30, clot lysis 30 minutes after maximal amplitude; ML, maximum 
lysis 60 minutes after the onset of clot formation; n/a, data not available from original publication 
Table 2 – Commonly employed VHA assays to measure coagulation and fibrinolysis 
 
 
VHA Platform Assay  Reagents used Description 
TEG KaolinTEG Re-calcified with calcium chloride and activated 
with Kaolin 
Assessment of clot formation, fibrin polymerisation and fibrinolysis 
via the intrinsic pathway 
TEG RapidTEG Re-calcified then activated with Kaolin and tissue 
factor (RapidTEG Reagent) 
Extrinsic pathway assessment of clot formation, fibrin 
polymerisation and fibrinolysis with faster results than Kaolin TEG. 
TEG Functional Fibrinogen TEG  Re-calcified then activated with lyophilized tissue 
factor and a platelet inhibitor that binds to 
glycoprotein-IIb/IIIa receptors (Functional 
Fibrinogen Reagent) 
Assessment of the fibrinogen contribution to clot formation after 
blocking platelets 
ROTEM EXTEM Re-calcified with calcium chloride (star-tem) and 
activated with thromboplastin (tissue factor) 
derived from rabbit brain (ex-tem) 
Assessment of clot formation, fibrin polymerisation and fibrinolysis 
via the extrinsic pathway 
ROTEM FIBTEM Re-calcified and platelets inhibited with 
cytochalasin D (fib-tem) and activated with ex-tem 
Assessment of the fibrinogen contribution to clot formation after 
blocking platelets 
ROTEM APTEM Re-calcified and fibrinolysis inhibited with 
aprotinin (ap-tem) and activated with ex-tem 
Assessment of clot firmness after blocking hyperfibrinolysis with 
aprotinin 
